A recent study out of Laval University finds many foods that are high in sodium and sugar on Canadian shelves are much cheaper than healthier, equivalent options.
Orforglipron, a GLP-1 receptor agonist in tablet form, has proven effective in treating obesity in a phase 3 trial, offering a potential alternative to injectable treatments like Wegovy and Ozempic.
The COVID-19 vaccine and treatment maker said Monday that it will pay $47.50 in cash for each share of development-stage drugmaker Metsera. That represents a premium of more than 42% to Metsera’s closing price last Friday.
